Quiz

Article

Clinician Quiz: Role of Adjunctive Tests in Diagnosing Iron Deficiency Anemia

Digital illustration of red blood cells. | Credit: Fotolia

Credit: Fotolia

Recognized by the World Health Organizaiton as the most common nutritional deficiency in the world, with an estimated global prevalence of around 30%, iron deficiency anemia, with its associations with adverse outcomes, poses a significant threat to individual- and population-level health.

Despite its elevated prevalence and knowledge of associations with adverse outcomes, diagnosis and management of iron deficiency anemia remains suboptimal in many settings. In 2020, the American Gastroenterological Association released updated guidelines for the gastrointestinal evaluation of iron deficiency. A 10-page document citing more than 2 dozen reference documents, the guideline provides specific updates in areas including adjunctive tests used in diagnosis, use of bidirectional endoscopy, and more!

Test your knowledge of these updates in the quiz below:

What is the recommended cutoff for ferritin levels when diagnosing iron deficiency anemia?


Reference:

1. Ko CW, Siddique SM, Patel A, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology. 2020;159(3):1085-1094. doi:10.1053/j.gastro.2020.06.046

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.